drugset / Trial / NCT06795204

Effects of HSK3486 on Cardiac Repolarization in Health Subjects (TQT)

NCT06795204

Phase 1 Completed 48 enrolled Haisco-USA Pharmaceuticals, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

To assess the effects of a single IV bolus of HSK3486 single dose on cardiac repolarization (QTc interval of the electrocardiogram, and to evaluate the safety and tolerability of a single IV bolus of HSK3486 in healthy subjects

Timeline

Start
2024-04-09
Primary completion
2024-05-19
Completion
2024-11-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Cipepofol Small molecule 0.4 mg/kg Intravenous
Comparator Moxifloxacin Small molecule 0.4 g Oral